Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

<h4>Background</h4>NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far.<h4>...

Full description

Bibliographic Details
Main Authors: Evgeniy Evdoshenko, Alexandra Stepanova, Maria Shumilina, Maria Davydovskaya, Natalia Khachanova, Nikolay Neofidov, Ivan Kalinin, Ekaterina Popova, Ekaterina Dubchenko, Natalia Pozhidaeva, Andrey Volkov, Stella Sivertseva, Anna Prilenskaya, Nadezhda Malkova, Denis Korobko, Ilona Vergunova, Sergey Shchur, Gleb Makshakov
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0217303

Internet

https://doi.org/10.1371/journal.pone.0217303

Similar Items